Consider this: although 8 in 10 adults say the cost of prescription drugs is unreasonable, only 3 in 10 say they are difficult to afford. This paradox results from complex system of drug pricing and reimbursement in the US, which often shields people from the true cost of the medications they take. This is one of several incentives that make bringing the price of prescription drugs down so difficult.
The 29th Pharmaceutical Outcomes and Policy Seminar will examine the business, economic, and ethical aspects of prescription drug pricing in the context of the complex reimbursement system. Experts will present new policies included in the Inflation Reduction Act and proposed policy solutions, including value-based drug prices and patent reforms. Student and faculty will deliberate the intended and unintended consequences of these policies on patient costs, access, disparity, and innovation – and whether any of these efforts will actually result in lower drug prices.
Location: This year’s seminar will take place in-person at the Gainesville campus. See map below for directions.
Dates: March 4-5, 2023
Registration coming soon, please check back.
Arthur J. Goldberg Distinguished Professor of Law, University of California Hastings Law Author of Drugs, Money and Secret Handshakes
Partner and Principal, Franklin Pharmaceutical Consulting
Professor Emeritus, Widener University
Adjunct Instructional Professor, University of Florida
Principal, CommonHealth Solutions
Adjunct Assistant Instructional Professor, University of Florida
Senior Director, Health Care Costs & Access, AARP Public Policy Institute
Associate Professor, Tufts Medical Center
Vice President, Pharmacy Relations & Chief Privacy Officer, Mark Cuban Cost Plus Drug Co.